Amendment to the Claims

The claimed invention is:

1. (Currently Amended) A compound of formula (Ia), (Ib), or (Ic):



(Ia)



(Ib)



(Ic)

or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate or solvate thereof, wherein:

R^1 is a group of the formula



, or

~~saturated, unsaturated, or aromatic C_3-C_{20} mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S~~, wherein R^1 can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy,

(C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, oxo, mercapto, (C_1-C_6)alkylthio, (C_1-C_6)alkoxy, (C_5-C_{10})aryl or (C_5-C_{10})heteroaryl, (C_5-C_{10})aryloxy or (C_5-C_{10})heteroaryloxy, (C_5-C_{10})ar(C_1-C_6)alkyl or (C_5-C_{10})heteroar(C_1-C_6)alkyl, (C_5-C_{10})ar(C_1-C_6)alkoxy or (C_5-C_{10})heteroar(C_1-C_6)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C_1-C_6)alkyl, (C_1-C_6)alkylamino(C_1-C_6)alkyl, di(C_1-C_6)alkylamino(C_1-C_6)alkyl, (C_5-C_{10})heterocyclyl(C_1-C_6)alkyl, (C_1-C_6)alkyl- and di(C_1-C_6)alkylamino, cyano, nitro, carbamoyl, (C_1-C_6)alkylcarbonyl, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylaminocarbonyl, di(C_1-C_6)alkylaminocarbonyl, (C_5-C_{10})arylcarbonyl, (C_5-C_{10})aryloxycarbonyl, (C_1-C_6)alkylsulfonyl, and (C_5-C_{10})arylsulfonyl;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, ~~(C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic~~, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, ~~(C_5-C_{10})heteroaryl-O-, (C_5-C_{10})heterocyclic-O-~~, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1-6}HN$-, (C_1-C_6)alkyl HN-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[(((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, ~~(C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-~~, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, ~~(C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-~~, (C_3-C_{10})cycloalkyl-NH-(C=O)- and (C_1-C_6)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, ~~heteroaryl, heterocyclic~~, cycloalkyl, alkoxy, phenoxy, amino of R^3 is optionally substituted by at least one substituent independently selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkyl, halo, H_2N-, $Ph(CH_2)_{1-6}HN$-, and (C_1-C_6)alkylHN-;

s is an integer from one to five;

and

R^6 is selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, ~~$(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclic~~, $(C_3\text{-}C_{10})$cycloalkyl, $(C_1\text{-}C_6)$alkyl-(SO_2)-, phenyl-(SO_2)-, H_2N-(SO_2)-, $(C_1\text{-}C_6)$alkyl-NH-(SO_2)-, $((C_1\text{-}C_6)\text{alkyl})_2N$-$(SO_2)$-, phenyl-NH-$(SO_2)$-, $(\text{phenyl})_2N$-(SO_2)-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, ~~$(C_5\text{-}C_{10})$heteroaryl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-~~, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, ~~$(C_5\text{-}C_{10})$heterocyclic-O-(C=O)-~~, $(C_3\text{-}C_{10})$cycloalkyl-O-(C=O)-, H_2N-(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, phenyl-NH-(C=O)-, ~~$(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-~~, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)-, $((C_1\text{-}C_6)\text{alkyl})_2N$-(C=O)-, $(\text{phenyl})_2N$-(C=O)-, phenyl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, ~~$(C_5\text{-}C_{10})$heteroaryl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-~~, and $(C_3\text{-}C_{10})$cycloalkyl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-;

where alkyl, alkenyl, alkynyl, phenyl, benzyl, ~~heteroaryl, heterocyclic~~, cycloalkyl, alkoxy, phenoxy, amino of R^6 is optionally substituted with at least one moiety independently selected from the group consisting of halo, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, phenyl, benzyl, $(C_5\text{-}C_{10})$heterocyclic, $(C_5\text{-}C_{10})$heteroaryl, $(C_1\text{-}C_6)$alkyl-SO_2-, formyl, NC-, $(C_1\text{-}C_6)$alkyl-(C=O)-, (C_3C_{10})cycloalkyl-(C=O)-, phenyl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-O-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-O-(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)-, phenyl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $((C_1\text{-}C_6)\text{alkyl})_2$-N-(C=O)-, phenyl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_{10})$cycloalkyl-O-, phenoxy, $(C_5\text{-}C_{10})$heterocyclic-O-, $(C_5\text{-}C_{10})$heteroaryl-O-, $(C_1\text{-}C_6)$alkyl-(C=O)-O-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-O-, phenyl-(C=O)-O-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-O-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-O-, O_2N-, amino, $(C_1\text{-}C_6)$alkylamino, $((C_1\text{-}C_6)\text{alkyl})_2$-amino, formamidyl, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-NH-, phenyl-(C=O)-NH-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-NH-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-(C=O)-[$(C_1\text{-}C_6)$alkyl)-N]-, phenyl-(C=O)-[$(C_1\text{-}C_6)$alkyl-N]-,

(C_1-C_6)alkyl-SO_2NH-, (C_3-C_{10})cycloalkyl-SO_2NH-, phenyl-SO_2NH-, (C_5-C_{10})heterocyclic-SO_2NH- and (C_5-C_{10})heteroaryl-SO_2NH-;

wherein the phenyl moiety of a R^6 substituent is optionally further substituted with at least one radical independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, perfluoro(C_1-C_6)alkyl and perfluoro(C_1-C_6)alkoxy,

~~with the proviso that R^1 is not a naphthyl or phenyl[1]; and~~

~~with the proviso that when R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members containing up to three N atoms, said N is other than -NH or -NC_{1-6}alkyl or if said N is -NH or -NC_{1-6}alkyl, then R^1 must be further substituted[2]; and~~

~~with the proviso that when R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members containing 1-3 heteroatoms independently selected from O and S, then R^1 must be further substituted.[3]~~

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Original) A compound of claim 1, wherein s is one to two; R^3 is hydrogen or (C_1-C_6)alkyl; and R^6 is H, (C_1-C_6)alkyl, or (C_3-C_{10})cycloalkyl.

10. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

11. (Cancelled)

12. (Cancelled)

---

13. (New) A compound 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof.

14. (New) A pharmaceutical composition comprising 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.